Related Experiment Video
Updated: Nov 29, 2025
Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures
Published on: October 30, 2009
Austrian recommendations for the management of essential thrombocythemia
Veronika Buxhofer-Ausch1,2, Sonja Heibl3, Thamer Sliwa4
1Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Fadingerstraße 1, 4020, Linz, Austria. veronika.buxhofer-ausch@ordensklinikum.at.
Insights
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) causing excessive platelet production. While complications like thrombosis and hemorrhage occur, treatments aim for prevention, and life expectancy is only slightly reduced.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Essential thrombocythemia (ET) is classified as a Bcr-Abl negative chronic myeloproliferative neoplasm (MPN) by the World Health Organization.
- ET involves clonal proliferation of hematopoietic stem cells, resulting in chronic thrombocytosis (overproduction of platelets).
- Common molecular drivers include mutations in JAK2 (Janus Kinase 2), CALR, and MPL genes.
Purpose of the Study:
- To provide a comprehensive overview of Essential Thrombocythemia (ET).
- To discuss the molecular basis, clinical manifestations, and management strategies for ET.
- To highlight the long-term outcomes and potential disease transformations in ET patients.
Main Methods:
- Review of World Health Organization (WHO) classification criteria for MPNs.
- Analysis of molecular mutations associated with ET.
- Summary of current therapeutic approaches and complication management.
Main Results:
- ET is characterized by high platelet counts due to stem cell proliferation.
- JAK2, CALR, or MPL mutations are present in most ET patients.
- Complications include thrombosis and hemorrhage, managed with antiplatelet and cytoreductive therapies.
- A minority of patients may progress to post-ET myelofibrosis or secondary leukemia.
Conclusions:
- ET is a manageable MPN with treatments focused on preventing thrombotic and hemorrhagic events.
- Long-term prognosis for ET patients is generally favorable, with only a slight decrease in life expectancy.
- Understanding molecular drivers and potential transformations is crucial for optimal patient care.
Abstract:
According to the World Health Organization (WHO) classification, essential (primary) thrombocythemia (ET) is one of several Bcr-Abl negative chronic myeloproliferative neoplasms (MPN). The classical term MPN covers the subcategories of MPN: ET, polycythemia vera (PV), primary myelofibrosis (PMF), and prefibrotic PMF (pPMF). ET is marked by clonal proliferation of hematopoietic stem cells, leading to a chronic overproduction of platelets. At the molecular level a JAK2 (Janus Kinase 2), calreticulin, or MPL mutation is found in the majority of patients. Typical ongoing complications of the disease include thrombosis and hemorrhage. Primary and secondary prevention of these complications can be achieved with platelet function inhibitors and various cytoreductive drugs including anagrelide, hydroxyurea and interferon. After a long follow up, in a minority of ET patients the disease transforms into post-ET myelofibrosis or secondary leukemia. Overall, life expectancy with ET is only slightly decreased.
